Join to view full profile
5900 Lake Wright DrNorfolk, VA 23502
Phone+1 757-466-8683
Fax+1 757-213-5846
Dr. Conkling is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1985 - 1988- Duke University HospitalResidency, Internal Medicine, 1982 - 1985
Ohio State University College of MedicineClass of 1982
Certifications & Licensure
VA State Medical License 1988 - 2028
NC State Medical License 1984 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
Publications & Presentations
PubMed
- 11 citationsTrilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage sm...Chao Li, Lowell L. Hart, Taofeek K. Owonikoko, Raid Aljumaily, Caio Max Sao Pedro Rocha Lima
Cancer Chemotherapy and Pharmacology. 2021-02-17 - 63 citationsSafety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyDaniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly
Clinical Cancer Research. 2021-02-10 - 79 citationsPhase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Aditya Bardia, Virginia G. Kaklamani, Sharon Wilks, Amy Weise, Donald A. Richards
Journal of Clinical Oncology. 2021-01-29
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: